company background image
KA logo

Kineta NasdaqCM:KA Stock Report

Last Price

US$0.56

Market Cap

US$7.1m

7D

-0.2%

1Y

-82.6%

Updated

25 Mar, 2024

Data

Company Financials +

KA Stock Overview

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives.

KA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Kineta, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kineta
Historical stock prices
Current Share PriceUS$0.56
52 Week HighUS$5.39
52 Week LowUS$0.49
Beta0
1 Month Change-77.95%
3 Month Change-85.68%
1 Year Change-82.58%
3 Year Changen/a
5 Year Changen/a
Change since IPO-85.18%

Recent News & Updates

Recent updates

Shareholder Returns

KAUS BiotechsUS Market
7D-0.2%0.2%1.3%
1Y-82.6%10.2%29.8%

Return vs Industry: KA underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: KA underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is KA's price volatile compared to industry and market?
KA volatility
KA Average Weekly Movement21.7%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: KA's share price has been volatile over the past 3 months.

Volatility Over Time: KA's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200712n/ahttps://kinetabio.com

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.

Kineta, Inc. Fundamentals Summary

How do Kineta's earnings and revenue compare to its market cap?
KA fundamental statistics
Market capUS$7.12m
Earnings (TTM)-US$14.10m
Revenue (TTM)US$5.44m

1.1x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KA income statement (TTM)
RevenueUS$5.44m
Cost of RevenueUS$9.02m
Gross Profit-US$3.58m
Other ExpensesUS$10.52m
Earnings-US$14.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.29
Gross Margin-65.80%
Net Profit Margin-259.08%
Debt/Equity Ratio25.2%

How did KA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.